The goal of this project is to determine the mechanism for complement enhancement of the humoral immune response to herpes simplex virus-I (HSV-1) and to test the use Of C3 as a natural adjuvant in development of vaccines. Our (in collaboration with project 3) preliminary results have demonstrated that the immune response to HSV-1 is impaired in mice deficient in either C3 or its receptor CD21. This observation is important for several reasons. It is the first observation that the complement system enhances the immune response to herpes virus. Second, it demonstrates a novel mechanism for HSV-l evasion of the immune response, i.e. by blocking complement activation. Third, it demonstrates that activation products of C3, i.e. C3d, could be used as an adjuvant for an HSV vaccine. This project will define the mechanism for complement enhancement and determine how HSV-I evades the complement enhancing effect in the first alm.
This aim will be performed in collaboration with project 3. The second and third alms will examine the importance Of local C3 synthesis and the effects C3 adjuvants have on B and T cell activation and tracking within the lymphoid compartment. Project 3 will provide the recombinant HSV-I virus for evaluating complement as a natural adjuvant in boosting the immune response. This project will interact with the first and second projects in analysis of complement enhancement of uptake and processing of antigen by antigen presenting cells. In summary, as a major mediator of the inflammatory response, complement provides an important adjuvant effect in the immune response to protein antigens. HSV-l evades this effect by inactivating C3 and limiting its covalent attachment. Clarifying the different stages in which complement is involved in the immune response to HSV, i.e. uptake and processing of antigen, upregulation of costimulators, B cell activation, antigen trapping, opsonization of virus in DH response, will be important for the design of complement related adjuvants in the absence of toxic side effects of inflammation.

Project Start
1998-09-01
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
115524410
City
Boston
State
MA
Country
United States
Zip Code
02115
Sen, Jayita; Liu, Xueqiao; Roller, Richard et al. (2013) Herpes simplex virus US3 tegument protein inhibits Toll-like receptor 2 signaling at or before TRAF6 ubiquitination. Virology 439:65-73
Brockman, Mark A; Verschoor, Admar; Zhu, Jia et al. (2006) Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells. J Virol 80:7111-7
Zhao, Xinyan; Deak, Eszter; Soderberg, Kelly et al. (2003) Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 197:153-62
Verschoor, Admar; Brockman, Mark A; Gadjeva, Mihaela et al. (2003) Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 171:5363-71
Tirabassi, Rebecca S; Ploegh, Hidde L (2002) The human cytomegalovirus US8 glycoprotein binds to major histocompatibility complex class I products. J Virol 76:6832-5
Furman, Margo H; Dey, Neelendu; Tortorella, Domenico et al. (2002) The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. J Virol 76:11753-6
Lorenzo, Mayra E; Jung, Jae U; Ploegh, Hidde L (2002) Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. J Virol 76:5522-31
Furman, Margo H; Ploegh, Hidde L; Tortorella, Domenico (2002) Membrane-specific, host-derived factors are required for US2- and US11-mediated degradation of major histocompatibility complex class I molecules. J Biol Chem 277:3258-67
Furman, Margo H; Ploegh, Hidde L (2002) Lessons from viral manipulation of protein disposal pathways. J Clin Invest 110:875-9
Karpova, Alla Y; Trost, Maren; Murray, John M et al. (2002) Interferon regulatory factor-3 is an in vivo target of DNA-PK. Proc Natl Acad Sci U S A 99:2818-23

Showing the most recent 10 out of 19 publications